Trial Profile
An Efficacy and Safety Study of Avelumab Plus SBRT in Malignant Mesothelioma (MPM)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 25 Oct 2023
Price :
$35
*
At a glance
- Drugs Avelumab (Primary)
- Indications Malignant-mesothelioma
- Focus Therapeutic Use
- 24 Jan 2023 Status changed from active, no longer recruiting to completed.
- 07 Mar 2022 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.
- 07 Mar 2022 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2023.